市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Annovis Bio, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
0.5
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.50 |
|
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 14.69% |
| 机构持股比例 | 16.09% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Merit Financial Group, Llc | 31 Dec 2025 | 81,316 |
| First National Trust Co | 31 Dec 2025 | 40,000 |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 18 Dec 2025 | 公告 | Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients |
| 16 Dec 2025 | 公告 | Annovis to Host Corporate Update Webinar on January 28, 2026 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合